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Abstract: KRAS mutations are responsible for resistance to anti-epidermal growth factor receptor
(EGFR) therapy in colorectal cancer patients. These mutations sometimes appear once treatment
has started. Detection of KRAS mutations in circulating cell-free DNA in plasma (“liquid biopsy”)
by droplet digital PCR (ddPCR) has emerged as a very sensitive and promising alternative to serial
biopsies for disease monitoring. In this study, KRAS G12V mutation was analyzed by ddPCR in
plasma DNA from 10 colorectal cancer patients and compared to six healthy donors. The percentage
of KRAS G12V mutation relative to wild-type sequences in tumor-derived DNA was also determined.
KRAS G12V mutation circulating in plasma was detected in 9 of 10 colorectal cancer patients whose
tumors were also mutated. Colorectal cancer patients had 35.62 copies of mutated KRAS/mL plasma,
whereas in healthy controls only residual copies were found (0.62 copies/mL, p = 0.0066). Interestingly,
patients with metastatic disease showed a significantly higher number of mutant copies than M0
patients (126.25 versus 9.37 copies/mL, p = 0.0286). Wild-type KRAS was also significantly elevated in
colorectal cancer patients compared to healthy controls (7718.8 versus 481.25 copies/mL, p = 0.0002).
In conclusion, KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR
and could be used as a non-invasive biomarker.
Keywords: KRAS; colorectal cancer; plasma; droplet digital PCR; circulating cell-free DNA
1. Introduction
In the past few years, cancer treatment has evolved markedly towards more personalized targeted
therapies. Metastatic colorectal cancer treatment frequently combines surgical resection with adjuvant
therapies that include monoclonal antibodies, such as EGFR-targeted antibodies (cetuximab and
panitumumab). However, only patients with KRAS wild-type tumors can benefit from anti-epidermal
growth factor receptor (EGFR) therapies, since it has been demonstrated that KRAS mutations
predispose to drug resistance [1]. Thus, tumor genotyping becomes crucial to decisions on clinical
treatment. However, secondary resistance could appear as a result of intratumoral heterogeneity,
clonal evolution and selection, i.e., subpopulations of tumor cells that become resistant to treatment
and proliferate [2]. Molecular analysis is routinely performed using DNA extracted from tissue, but
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taking serial biopsies entails many difficulties and is not always possible due to several factors: Tumors
or metastases not accessible for biopsy, insufficient material available for genotyping, discomfort for
the patient, risk of tumor spread due to the procedure itself, potential clinical complications, economic
considerations, difficulties in acquiring samples from different medical centers, and/or treatment
contraindications [3,4]. We should be able to overcome these issues and rapidly identify biomarkers
in a cost-effective and non-invasive manner to monitor treatment response at different time points
during the course of disease. To this end, DNA fragments released by tumor cells, which can be
found circulating in plasma and are termed as circulating tumor DNA (ctDNA), have given rise to the
concept of “liquid biopsy” [2]. The main problem impeding more widespread use of liquid biopsy is
that certain clinical scenarios exist, particularly at early stages of disease, where levels of circulating
tumor DNA are below the limits of detection of currently applied techniques [3].
In recent years, many efforts have been made to develop highly specific and sensitive techniques
for detection of low-abundance KRAS mutations, including real-time PCR, coamplification at lower
denaturation temperature-PCR (COLD-PCR), pyrosequencing, or digital PCR [5,6]. Nowadays,
digital PCR has become one of the mainstream methodologies for rare mutation detection, but this
partition-based technique is actually not new. The term “digital PCR” was coined and described in
1999 by Vogelstein et al. [7] in a study aimed at detecting a variant of a single-nucleotide polymorphism
of the RAS oncogene in samples where wild-type sequences were predominant. Indeed, in the previous
decade, this method was used under the names “single molecule PCR” or “limiting dilution PCR”
(reviewed in [8]). However, the results of the first digital PCR studies were limited by technical and
economic hurdles, and it was not until the development of new instrumentation based on nanofluidics
and emulsion chemistries that this technology has become more affordable and available for routine
implementation [9].
Droplet digital PCR (ddPCR) technology performs a water-in-oil emulsion of the PCR reaction
mixture, which allows for massive sub-partitioning into hundreds to millions of independent reactions,
creating a synthetic enrichment effect that dramatically increases the capability of detecting rare
mutations present at very low levels in the sample [10]. After amplification in a thermal cycler, the
number of positive partitions (where the amplified target sequence is detected) and negative partitions
(in which there is no signal of amplification), are counted as a binary or “digital” system. A Poisson
correction is then applied for quantification of the mean number of target sequences per partition [11].
Several platforms of ddPCR have been developed by different manufacturers, such as Fluidigm,
Sysmex Inostics (BEAMing Digital PCR), Bio-Rad Laboratories, or RainDance Technologies. Some of
them have already been tested for detection of KRAS mutations producing different results [12–20].
The present study is aimed at evaluating the sensitivity and reproducibility of a new droplet digital
PCR system (Bio-Rad QX-200 platform) for detection of KRAS G12V mutation in samples of plasma
where this mutation has previously been confirmed. This particular mutation was chosen because
it has been associated with a worse progression in our series of patients, showing a markedly poor
clinical outcome, high rate of post-operative complications, and short time of survival.
2. Results
The human adenocarcinoma cell line SW480, which harbors the KRAS G12V mutation in
homozygosis, was used to assess the analytical sensitivity of the assay. We performed serial dilutions of
DNA from the SW480 cell line (from 5 to 12.5 pg/µL) into a constant background of wild-type genomic
DNA from leukocytes (130 ng per well). Non-diluted cell line-derived DNA showed a fractional
abundance of 99.99% of mutant DNA, with a residual presence of wild-type copies. KRAS G12V
mutation could be detected even at a dilution of 1/4000, which corresponds to a fractional abundance
of 0.025%, maintaining the linearity of the assay (R2 = 0.998).
We only detected wild-type KRAS sequences and no mutant copies in 50 ng/µL DNA extracted
from healthy donor leukocytes (n = 4). Background from water added to the reaction mixture instead
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of DNA was also analyzed (n = 4) and no mutant copies were detectable, although a limited number
of positive events for wild-type sequences were found.
In DNA extracted from fresh-frozen portions of tumor mucosa, the percentage of KRAS G12V
mutation relative to wild-type sequences was 36.83% (n = 10, median).
We analyzed the presence of KRAS G12V mutation in the plasma of six healthy donors. In three
of these donors, we detected very low concentrations, between 1.25 and 1.87 copies/mL of plasma.
In the other three, only wild-type sequences of KRAS were detected.
KRAS G12V mutation was detected in all colorectal cancer patients tested, with the exception of
one. This sample was obtained from a patient with a tumor staged as T1N0M0 (Table 1). Colorectal
cancer patients had 35.62 copies of mutated KRAS per milliliter of plasma (median), whereas in healthy
controls only residual copies were found (0.62 copies/mL, p = 0.0066). Patients with metastatic disease
showed a significantly higher number of mutant copies/mL plasma than M0 patients (median, 126.25
and 9.37 copies/mL, respectively, p = 0.0286).
Table 1. Clinical features of patients included in the study.
Patient ID Age (Years) Sex TNM Stage Survival KRAS G12V(Copies/mL)
Fractional
Abundance (%)
53 85 M T3N0M0 IIa 6 years 7.50 62.79
113 80 F T1N0M0 I >2 years 0.00 40.42
118 64 M T3N2M1Liver IV >2 years 25.00 6.16
130 49 F T3N1M1Liver IV 8 months 197.5 20.60
158 84 M T4N0M0 IIb 1 year 11.25 34.87
220 69 M T4N2M1Bone IV 2 months 55.00 38.80
257 85 M T3N0MX IIa 8 days 46.25 53.20
258 86 M T3N0MX IIa 20 days 110.00 33.70
522 77 M T3N0M0 IIa 18 months 13.75 23.76
532 60 M T4N1M2Liver Lung IV 10 days 2412.5 77.82
This cohort of KRAS G12V patients showed a markedly poor clinical outcome, high rate of post-operative
complications, and short time of survival.
The amount of wild-type KRAS circulating in plasma was also significantly elevated in colorectal
cancer patients in comparison to healthy controls (median, 7718.8 versus 481.25 copies/mL, respectively,
p = 0.0002).
3. Discussion
KRAS mutations have become routinely used as molecular biomarkers in clinical practice for
management and monitoring of metastatic colorectal cancer patients [21]. Given the fact that patients
carrying KRAS mutations do not respond to anti-EGFR antibodies (cetuximab and panitumumab),
a precise, sensitive, and specific method of KRAS genotyping is essential for decision making.
Furthermore, mutational status of KRAS should be determined not only at diagnosis, but also during
treatment follow-up. Point mutations often appear as a result of intratumoral heterogeneity and clonal
selection in primary tumors and/or metastases as they evolve during disease progression, leading
to the development of secondary drug resistance [2]. Determination of KRAS mutations in plasma
is based on the presence of circulating tumor DNA (ctDNA) and offers the possibility of constant
monitoring without the need for serial biopsies. This alternative source of DNA for tumor genotyping
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is termed “liquid biopsy” and has gained increasing interest because a blood draw is less invasive,
faster, and more feasible than tissue sampling [3].
Tumors from patients enrolled in this study were previously proven to carry KRAS G12V mutation
as determined by Sanger sequencing from fresh-frozen tumors. Of all the most common KRAS codon
12 mutations, we chose G12V because it has been related to a more aggressive phenotype and worse
progression of the disease [22–27]. In fact, the cohort of KRAS G12V patients that we included in this
study was remarkable because of its poor clinical outcome, high rate of post-operative complications,
and short time of survival (Table 1).
The main shortcoming of our study was the limited number of mutation-carrying patients
available for analysis (n = 10). Although the G12V mutation is considered to be one of the most
frequent KRAS codon 12 mutations in colorectal cancer patients—particularly in those with liver
metastasis (ranging from 20.5% to 32.8%) [21,27]—the number of KRAS G12V-mutated samples in our
population of study at La Paz University Hospital was very low (13 out of 554 total patients analyzed,
representing 15.12% of total KRAS codon 12 mutations).
Our aim was to evaluate the sensitivity and reproducibility of a new droplet digital PCR platform
for detection of previously confirmed KRAS G12V mutation in plasma samples.
We achieved high analytical sensitivity in the assay, reaching 1/4000 dilution, corresponding to
a fractional abundance of 0.025%. Sanmamed et al. [28] recently reported a higher sensitivity for the
detection of BRAF V600E mutation in plasma of melanoma patients using the same ddPCR platform
(a fractional abundance of 0.005%). However, their limit of detection was established as 1 copy of
mutant DNA/mL. Oxnard et al. [16] also reported a detection sensitivity of 5 to 50 mutant copies in
a background of 10,000 wild-type copies using serial dilutions of mutant DNA, which corresponds
to a prevalence between 0.005% and 0.01%, depending on the mutation assayed (including EGFR
L858R, EGFR exon 19 deletion, and KRAS G12C). These discrepancies are probably a consequence of
differences in data normalization criteria and/or methodologies for assay sensitivity analysis, such as
serial dilution preparation and starting concentration of mutant DNA (e.g., 16 ng/µL in Sanmamed’s
article versus 5 ng/µL in our study).
Given the fact that positive mutation events were still detectable at 1/4000 dilution, we could
have tested further dilutions until the number of counts reached zero. However, background of
mutated copies in healthy donors ranged between 1.25 and 1.87 copies/mL of plasma in three of
these donors, so we established the positivity threshold at 1.87 copies/mL. Thus, in our study, to
be considered as positive for the mutation, plasma samples from colorectal cancer patients had to
contain more than 1.87 copies/mL. Other authors used a threshold of 0.5 to 1 copies/mL for a positive
result, even when a healthy donor showed 12 copies/mL [28]. In some reports, the threshold varies
depending on the mutation assayed and the number of cases correctly identified as positive (from 0.5 to
6 copies/mL) [16]. These differences in thresholds raise awareness about the need for a consensus and
the adoption of some guidelines by the scientific community to standardize experimental procedures
in ddPCR technology [11].
The ddPCR platform used in this study has shown a strikingly high sensitivity of detection.
Comparative studies have shown that ddPCR exceeds other methods, such as real-time PCR
or pyrosequencing [29–32], which are also more expensive, labor-intensive, and require more
manipulation, thus increasing the risk of contamination. It has been recently reported that ddPCR
can be performed in liquid biopsy samples from breast cancer patients for <€1000 per patient in
reagents and <€50 per time point, currently making it much more cost-effective than approaches where
whole-genome sequencing is used. In addition, implementation of this analysis in routine clinical
management seems feasible with respect to time frame, since a ddPCR test on patient plasma samples
can be performed within 1 day [33].
In our study, the percentage of KRAS G12V in tumor-derived DNA was 36.83% (n = 10, median).
This percentage could not be correlated to either the number of copies per mL of plasma or to the
presence of metastasis. Intratumoral heterogeneity (i.e., clones or subpopulations of cells with different
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genetic profiles inside the tumor) and differences in tumor cellularity of biopsies (i.e., the fragment of
mucosa that is taken for analysis may not be representative of the whole tumor, introducing a bias due
to tumor fragment contamination by normal cells) [20,34] could explain the lack of correlation between
the percentage of mutant DNA in the tumor and the rest of the parameters analyzed in this study.
We observed that colorectal cancer patients had mutated KRAS circulating in plasma as well
as elevated levels of wild-type KRAS in comparison to healthy controls (p = 0.0066 and p = 0.0002,
respectively). These results are in agreement with recent reports, where circulating tumor DNA levels
showed a quantitative predictive value of poor clinical outcome in melanoma and breast cancer [28,33].
However, elevated levels of wild-type DNA should not be used as cancer biomarkers, since they often
rise in many other nonmalignant conditions, such as heart dysfunction, inflammation, pregnancy,
heavy smoking, or after exercise or trauma [2,3,35].
It is also noteworthy that patients with metastatic disease showed a significantly higher number of
mutant copies/mL plasma than M0 patients (p = 0.0286). In line with these results, Bettegowda et al. [4]
reported that detectable levels of ctDNA were present in 49% to 78% of patients with localized tumors
versus 86% to 100% of patients with metastatic colon, pancreas, breast, and gastroesophageal tumors.
In their study, the concentration of ctDNA in plasma increased with stage and was predictive of a
lower survival rate, whereas more than a half of patients with early stages of disease had undetectable
levels of ctDNA. Taking these observations into account, it is not surprising that we found one patient
in our series with localized stage I disease where we could not detect mutant DNA circulating in
plasma. Future studies will be conducted and will include a higher number of T1 patients in order to
verify whether levels of mutated copies in circulating cell-free DNA at early stages are too low to be
detected by our method.
Reinert et al. [35] has recently found a close correlation between the amount of mutant DNA
detected by ddPCR in serial post-surgery plasma samples and the clinical disease course. In their
retrospective study, circulating tumor DNA levels decreased after tumor resection, radiofrequency
ablation, or chemotherapy, but they increased again in the previous months to diagnosis of clinical
recurrence. In all relapsing patients, a raise in ctDNA anticipated the appearance of recurrent disease
up to 10 months earlier than conventional diagnostic tools, such as computed tomography (CT).
However, ctDNA was undetectable in non-relapsing patients. This study highlights the relevance of
detecting and quantifying ctDNA by ddPCR during disease follow-up: the procedure provides an early
biomarker of recurrence and offers the possibility to evaluate the response to treatment, shortening the
time needed to make changes in therapeutic regimens and clinical interventions.
Analysis of molecular markers in ctDNA could also have significant implications for early
detection and prevention of disease, identifying pathogenic changes before symptoms develop.
Epidemiology research traditionally has focused on risk factors associated with colorectal cancer,
whereas molecular pathology has explored the molecular characteristics of tumors involved in
carcinogenesis and tumor behavior. These two approaches have now converged in a relatively new
field termed “molecular pathological epidemiology (MPE)”, based on the molecular classification of
cancer into distinct subtypes [36]. MPE is emerging as a new standard of medicine for intrinsically
heterogeneous diseases, especially cancer [37]. The concept of MPE, which was coined by Ogino
and Stampfer, consists of multidisciplinary investigation of the relationship between exogenous and
endogenous factors of interest for tumor initiation, progression, and response to treatment [36,38].
Among its major applications are molecular biomarker discovery and validation for risk assessment,
early detection, diagnosis, and decision making on interventions. By providing a better definition
of phenotype, MPE could improve our understanding of etiologic heterogeneity, the relevance of
personalized preventive strategies depending on particular risk factors, exposure (dietary, lifestyle,
microbial and chemical), host susceptibilities, and individual profiles [37]. Thus, the strategy proposed
in this study for the analysis of tumor molecular signatures on liquid biopsy could impact large-scale
population studies and contribute to the expansion of the MPE research area.
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A growing body of evidence demonstrates the utility of ddPCR, not only to identify specific
mutations, but also to monitor disease progression and the emergence of drug resistance in many
types of cancers, such as colorectal cancer, melanoma, lung or breast cancer [16,20,28,39]. In fact, it is
gaining consideration as one of the most effective methods of measuring minimal residual disease in
oncologic conditions, such as melanoma [40], multiple myeloma, mantle cell lymphoma, and follicular
lymphoma [31].
To our knowledge, this is the first study to describe the detection of KRAS G12V mutation
circulating in plasma using this particular droplet digital PCR platform. The reported results come
from a limited series of patients which requires further validation, although our data show that KRAS
G12V mutation is detectable in plasma of colorectal cancer patients using this ddPCR system, and
could be useful as a non-invasive biomarker of drug resistance and response to treatment during
disease progression.
4. Materials and Methods
4.1. Cells
We purchased the SW480 human adenocarcinoma cell line from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were cultured at 37 ˝C in a 5% CO2 humidified
atmosphere with Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Invitrogen, Life Technologies,
San Diego, CA, USA) medium supplemented with 10% heat inactivated fetal bovine serum and 1%
penicillin/streptomycin.
4.2. Patients and Healthy Subjects
We selected 10 patients with colorectal cancer who had undergone resection of primary tumors
from 2004 to 2013 in the Department of General Surgery at La Paz University Hospital (PI-138, Madrid,
Spain) (n = 8) and General University Hospital of Albacete (05/12, Albacete, Spain) (n = 2), according
to a protocol approved by the Ethics Committee of these institutions. The patients had KRAS mutated
tumors (G12V) that had been detected by sequencing. In all cases, histopathologic analysis revealed
the tumors to be adenocarcinomas.
Six healthy donors were included in the study after informed consent was provided.
4.3. Sample Collection
Blood samples were collected in EDTA tubes (9 mL) immediately before surgery. All samples
were centrifuged at 1800ˆ g for 10 min. Plasma was collected, subjected to a second centrifugation at
3000ˆ g for 10 min, aliquoted and stored at ´80 ˝C until analysis.
4.4. DNA Extraction
Circulating DNA from plasma and genomic DNA from cells and tumors were extracted with the
QIAamp DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. DNA quantification was performed in a NanoDrop spectrophotometer (Thermo Scientific,
Waltham, MA, USA).
4.5. Mutation Detection by ddPCR
ddPCR assays were performed with the Prime-PCR™ ddPCR™ Mutation Detection Assay Kit
(Bio-Rad, Hercules, CA, USA) using an amplicon of 57 nt. DNA from the SW480 cell line was used as a
positive control and DNA from leukocytes of a healthy donor served as a negative control. Background
from water added to the reaction mixture instead of DNA was analyzed. This study was performed on
a QX200 Droplet Digital PCR System (Bio-Rad), consisting of a C1000 Touch Thermalcycler, a QX200
Droplet Generator, and a QX200 Droplet Reader. The PCR reaction mixture (20 µL) contained 10 µL of
ddPCR Supermix (no dUTP) for probes, 1 µL of each primer/probe mix (target and reference, labeled
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with HEX and FAM fluorophores, respectively), and 8 µL of plasma-extracted DNA. A total amount of
130 ng of DNA was added per well in case of positive and negative controls and in DNA extracted from
tumors. The thermal cycling started with 10 min at 95 ˝C, followed by 40 cycles of 94 ˝C for 30 s and
55 ˝C for 60 s. Results were analyzed using Quantasoft v.1.7 software (Bio-Rad) and reported as copies
per mL of plasma or % of mutant DNA in the tumor. Four replicates of each sample were analyzed.
4.6. Statistical Analyses
All statistical calculations were done using GraphPad InStat software. The Mann-Whitney test for
significance was utilized because some of the data were not normally distributed and this test makes
no assumption on data distribution.
5. Conclusion
KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR and could
be used as a non-invasive biomarker of drug resistance during disease progression.
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KRAS Kirsten rat sarcoma viral oncogene homolog
EGFR epidermal growth factor receptor
BRAF B-Raf proto-oncogene serine/threonine kinase
DdPCR droplet digital PCR
CtDNA circulating tumor DNA
COLD-PCR coamplification at lower denaturation temperature-PCR
BEAMing beads, emulsions, amplification, and magnetic
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